The Roundup – January 16, 2025

Welcome to BioCT’s weekly roundup! Read on for the latest industry news, resources, and opportunities.

• AbbVie partners with Simcere Pharma unit to develop myeloma drug
• AstraZeneca, CRISPR tools supplier ink gene editing enzyme licensing deal
• Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3
• Boehringer Ingelheim: New partnership and significant pipeline progress
• Charter Oak State College Teams with Google to Launch CT Online AI Academy
• GSK-allied Ouro Medicines throws its hat into burgeoning TCE ring
• GSK kicks off JPM dealmaking with $1B+ buyout of IDRx and its rare cancer drug
• Lilly finances new $500M biotech fund managed by a16z
• Lilly to acquire cancer biotech Scorpion, which shares a co-founder with Loxo
• Lilly ventures into pulmonary fibrosis with startup Mediar
• Normunity nabs $75M Series B to advance T cell engager and launch first trial
• RNAConnect Debuts the new UltraMarathonRT® RT-qPCR Kit to Improve Reliability of Gene Expression Analysis
• UConn Today: 2024: A Year of Research That Mattered

• CT biotech firm secures $9M to advance oral treatment for inflammatory bowel disease
• Dozens of bills proposed on opening day of CT legislative session. Here’s a look.
• Lamont frames a 2025 agenda, stinting on solutions
• New coalition seeks legislation to force transparency for PBMs
• New Haven-based biotech raises $14.5M to expand PTSD treatment program
• XingImaging Opens State-of-the-Art Research Facility in New Haven

Join Aon on Jan 23 in their New York Office for a 360-degree view of the IPO process, offering practical advice from experienced professionals who have helped prepare companies transition to the public market.

Don’t miss the chance to hear opening remarks from Miles “Deuce” McBride, a professional basketball player with the New York Knicks.

The panel will be moderated by Elizabeth Mutton, and will feature Jennifer Wong, Jordan Saxe, Chris Brandes, and Joseph A. Herz.

Topics include:

• Key Financial and Accounting Considerations: Insights on preparing financial statements, GAAP compliance, and navigating SEC reporting.
• Risk Management Strategies: Aon’s perspective on mitigating risks and securing the right insurance solutions, including Directors and Officers (D&O) liability.
• Compliance and Regulatory Insights: Legal experts will guide you through regulatory frameworks, governance, and Sarbanes-Oxley Act (SOX) requirements.

Register here.

BioCT’s 1^st Facilities and Lab Operations Roundtable Recap

The launch of the Facilities and Laboratory Operations (FLO) Roundtable was a huge success with over 60 participants. The laboratory sustainability panel discussed how resource-intensive lab spaces and lab managers can utilize the BioCT network to cost-efficiently mitigate environmental impacts . Adopting sustainable practices decreases the generation of ~5.5 million metric tons of plastic waste each year – the equivalent of filling 67 cruise liners!

Thank you to our panelists, and to Winstanley Enterprises for providing their state-of-the-art conference room at 101 College Street.

Suggestions for future topics or sponsorships, can be submitted to Kim Kelly at kkelly@bioct.org.

Thank you to our generous sponsors:

In addition to other duties, this individual will lobby and advocate for positions on public policy issues at the state level with legislators, governors, government officials and other stakeholders. Represent Boehringer Ingelheim and its interests with elected officials, government stakeholders, trade associations, coalitions, and in legislative forums in state capitols. Provide insights regarding political dynamics, legislative and regulatory developments to internal customers. 

For complete details, please click here.

• Cygnus  |  Developing processors to enable real-time, closed-loop computing in neural interface systems.
• EXOSIG  |  Building a blockchain-integrated platform to facilitate the discovery of exosomal microRNA biomarkers, with the goal of enhancing the prediction and diagnosis of neurodegenerative diseases.
• Raman Noodle  |  Advancing stimulated Raman scattering technology to enable the molecular fingerprinting of samples without the need for stains or reagents.
• TheraJan  |  Scaling USDA-approved EGFR/HER2 peptide cancer immunotherapeutics.

Participating teams are based out of Yale University research labs. Educational programming and mentorship will give founders essential tools to spin out their research into biotech companies.

Our mailing address is:
BioCT
93 Shennecossett Road
Groton, CT 06340

Too many emails?
You can unsubscribe from this list.